60 research outputs found

    Generalized Quadratic Revenue Functions

    Get PDF
    In this paper we focus on specification of revenue functions in their dual price space. We consider two distance functions, both dual to the revenue function: Shephard output distance function and the directional output distance function, both in price space. The former is multiplicative, satisfying homogeneity, the latter is additive satisfying transitivity. Functional equation methods yield translog specification for the Shephard case and quadratic for the directional case. Monte Carlo evidence suggests that the quadratic specification more precisely represents technology.

    Increase of the Density, Temperature and Velocity of Plasma Jets driven by a Ring of High Energy Laser Beams

    Full text link
    Supersonic plasma outflows driven by multi-beam, high-energy lasers, such as Omega and NIF, have been and will be used as platforms for a variety of laboratory astrophysics experiments. Here we propose a new way of launching high density and high velocity, plasma jets using multiple intense laser beams in a hollow ring formation. We show that such jets provide a more flexible and versatile platform for future laboratory astrophysics experiments. Using high resolution hydrodynamic simulations, we demonstrate that the collimated jets can achieve much higher density, temperature and velocity when multiple laser beams are focused to form a hollow ring pattern at the target, instead of focused onto a single spot. We carried out simulations with different ring radii and studied their effects on the jet properties. Implications for laboratory collisionless shock experiments are discussed.Comment: 5 pages, 4 figures, Accepted to HED

    The Limits to Moral Erosion in Markets: Social Norms and the Replacement Excuse

    Full text link
    This paper studies the impact of a key feature of competitive markets on moral behavior: the possibility that a competitor will step in and conclude the deal if a conscientious market actor forgoes a profitable business opportunity for ethical reasons. We study experimentally whether people employ the argument "if I don’t do it, someone else will" to justify taking a narrowly self-interested action. Our data reveal a clear pattern. Subjects do not employ the "replacement excuse" if a social norm exists that classifies the selfish action as immoral. But if no social norm exists, subjects are more inclined to take a selfish action in situations where another subject can otherwise take it. By demonstrating the importance of social norms of moral behavior for limiting the power of the replacement excuse, our paper informs the long-standing debate on the effect of markets on morals

    Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

    Get PDF
    Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

    The Visibility of (In)security: The Aesthetics of Planning Urban Defences Against Terrorism

    Get PDF
    Urban defences against terrorism have traditionally been based on territorial interventions that sought to seal off and surveil certain public and private spaces considered targets. Lately, though, a much wider range of crowded and public spaces have been viewed as potential targets and thus have been identified as requiring additional security. This has immense implications for the experience of the ‘everyday’ urban landscape. Drawing on contemporary notions that incorporate the study of aesthetics and emotions within critical security and terrorism studies, this article discusses the visual impact of counter-terrorism security measures. It analyses the ‘transmission’ of symbolic messages, as well as the variety of ways in which security might be ‘received’ by various stakeholders. The analysis takes place against the backdrop of concern that obtrusive security measures have the capacity to radically alter public experiences of space and in some cases lead to (intended and unintended) exclusionary practices or a range of negative emotional responses. The article concludes by outlining a ‘spectrum of visible security’ ranging between traditional obtrusive fortified approaches and approaches that embed security features seamlessly or even ‘invisibly’ into the urban fabric

    Output Substitution in Multi-Species Trawl Fisheries: Implications for Quota Setting

    Full text link
    corecore